Get the Stockscreener App
31.12
1.80%
0.55
Pre-market:
31.12
Smith Nephew Plc Adr stock is traded at $31.12, with a volume of 1.69M.
It is up +1.80% in the last 24 hours and up +3.60% over the past month.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
See More
Previous Close:
$30.57
Open:
$30.87
24h Volume:
1.69M
Relative Volume:
1.19
Market Cap:
$13.10B
Revenue:
$6.18B
Net Income/Loss:
$626.40M
P/E Ratio:
21.69
EPS:
1.435
Net Cash Flow:
$848.81M
1W Performance:
+2.27%
1M Performance:
+3.60%
6M Performance:
-8.69%
1Y Performance:
-1.74%
1-Day Range:
$30.75
$31.23
1-Week Range:
$29.54
$31.23
52-Week Range:
$28.55
$38.79
Smith Nephew Plc Adr Stock (SNN) Company Profile
Compare SNN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
31.12 | 13.10B | 6.18B | 626.40M | 848.81M | 1.435 |
ABT
Abbott Laboratories
|
104.49 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-14-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Mar-12-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-24 | Downgrade | Berenberg | Buy → Hold |
| Nov-01-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-24 | Initiated | Deutsche Bank | Buy |
| Jun-05-24 | Upgrade | UBS | Neutral → Buy |
| Nov-28-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-03-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-31-23 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-13-23 | Initiated | Stifel | Hold |
| Aug-08-23 | Upgrade | UBS | Sell → Neutral |
| Apr-27-23 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-12-22 | Initiated | Citigroup | Buy |
| Nov-28-22 | Downgrade | UBS | Neutral → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-28-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-15-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-22 | Upgrade | Redburn | Sell → Neutral |
| Jun-09-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-18-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-01-20 | Initiated | Barclays | Overweight |
| Jul-29-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-21-19 | Initiated | Citigroup | Buy |
| Nov-12-19 | Initiated | Bernstein | Outperform |
| Jul-23-19 | Upgrade | Berenberg | Hold → Buy |
| Feb-08-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Jan-02-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-01-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-25-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-11-17 | Initiated | Canaccord Genuity | Buy |
| Feb-27-17 | Downgrade | Goldman | Buy → Neutral |
| Jan-19-17 | Initiated | HSBC Securities | Hold |
| Dec-08-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-06-16 | Downgrade | Berenberg | Buy → Hold |
| Feb-26-16 | Initiated | Cantor Fitzgerald | Hold |
View All
Smith Nephew Plc Adr Stock (SNN) Latest News
Smith & Nephew Advances $250 Million Share Buyback, Repurchasing Over 1 Million Shares in Latest Week - Kalkine Media
Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care - Sahm
Smith & Nephew (NYSE: SNN) leaders buy ADS through employee stock plan - Stock Titan
Smith & Nephew Executives Acquire American Depositary Shares via Employee Stock Purchase Plan on July 10, 2026 - Kalkine Media
REGSmith & Nephew PlcDirector/PDMR Shareholding - TradingView
Smith+Nephew introduces groundbreaking LYNX™ COBLATION™ Laryngeal Wand for ENT surgeons - Sahm
Smith+Nephew introduces groundbreaking LYNX COBLATION Laryngeal Wand for ENT surgeons - Finviz
How Are Smith & Nephew (LSE:SN.) And ConvaTec (LSE:CTEC) Steering UK MedTech Sentiment? - Kalkine Media
SNN stock holds steady as Smith & Nephew keeps its investor focus - AD HOC NEWS
Explosive Growth in AI for Orthopedic Surgery Market: $0.87 Billion by 2030 at 27.2% CAGR - GlobeNewswire Inc.
Why Is Smith & Nephew (LSE:SN.) Stock Being Watched After an Activist Investor Move? - Kalkine Media
Smith & Nephew plc ADR highlights its medical technology portfolio as investors weigh long-term grow - ad-hoc-news.de
Smith & Nephew plc (NYSE:SNN) Caviar Cruise Screen Analysis - ChartMill
REGENETEN bioinductive implant from Smith & Nephew plcshoulder tendon repair with a quiet patch - Ad-hoc-news.de
ALLEVYN COMPLETE CARE Foam Dressing from Smith & Nephew plcnext-generation comfort for demanding - AD HOC NEWS
NPWA Forecast — Price Target — Prediction for 2027 - TradingView
Smith & Nephew consensus in focus, analysts keep a cautious hold on the shares - AD HOC NEWS
939163 Forecast — Price Target — Prediction for 2027 - TradingView
India Advanced Wound Dressing Market Size & Outlook, 2033 - Grand View Research
Smith & Nephew strategy under new CEO, shares trade stable in London - AD HOC NEWS
Smith & Nephew StockThursday technical picture and trading range - ad-hoc-news.de
Why Smith & Nephew’s PICO Single Use Negative Pressure System is changing tricky wound care - AD HOC NEWS
Why Smith & Nephew’s LEGION Revision Knee still matters in tough cases - AD HOC NEWS
Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty - Sahm
Smith & Nephew plc (ADR) stock (US83175M2052): U.K. medtech group draws interest after recent debt m - AD HOC NEWS
Smith & Nephew (NYSE: SNN) execs add ADS via dividend reinvestment - Stock Titan
Dell Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact - Sahm
SNNSmith & Nephew plc ADR Stock Price and Quote - Finviz
Smith & Nephew plc stock (GB0009223206): orthopedics specialist lifts guidance after solid Q1 - AD HOC NEWS
Smith & Nephew stock (GB0009223206): sets sterling final dividend ahead of May payout - AD HOC NEWS
DowngradesStock ScreenerSnapshot - Finviz
Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,* - Sahm
New data for Smith+Nephew’s CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-years - ChartMill
Smith & Nephew plc (ADR) stock (US83175M2052): Why Google Discover changes matter more now for medte - AD HOC NEWS
Smith & Nephew plc (ADR) stock (US83175M2052): Why its medtech innovation edge is suddenly worth a c - AD HOC NEWS
Smith & Nephew PLC (NYSE:SNN) Passes the Caviar Cruise Screen for Quality Investing - ChartMill
Smith & Nephew plc (ADR) Stock: Global Medtech Leader Faces Evolving Orthopedics and Sports Medicine - AD HOC NEWS
Smith & Nephew plc (ADR) stock faces pressure amid regulatory hurdles and slowing ortho demand - AD HOC NEWS
Smith & Nephew plc (ADR) Stock (ISIN: US83175M2052) Faces Headwinds Amid Medtech Sector Slowdown - AD HOC NEWS
Smith+Nephew launches next-generation ALLEVYN COMPLETE CARE Foam Dressingdesigned for high performance in wound management and pressure injury prevention - Finviz
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressingdesigned for high performance in wound management and pressure injury prevention - ChartMill
NVIDIA Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026 - Sahm
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026 - Sahm
Smith Nephew Plc Adr Stock (SNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):